Mary E Aronow1, Emily Y Chew. 1. Division of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA.
Abstract
PURPOSE OF REVIEW: This review provides a perspective on the Age-related Eye Disease Study 2 (AREDS2) including a summary of the goals and rationale of the study, major findings, subsequent management recommendations, and questions that remain to be answered. RECENT FINDINGS: The primary goal of the AREDS2 was to evaluate the efficacy and safety of lutein plus zeaxanthin and/or omega-3 long-chain polyunsaturated acid supplementation in reducing the risk of developing advanced age-related macular degeneration (AMD). AREDS2 also investigated the effects of omitting β-carotene and reducing the concentration of zinc from the original AREDS formulation. Although primary analysis from the AREDS2 did not reveal a benefit of daily supplementation with lutein/zeaxanthin on AMD progression, secondary exploratory analyses suggested that lutein/zeaxanthin were helpful in reducing this risk. Comparison of low-dose to higher-dose zinc showed no significant benefit. SUMMARY: The overall evidence on the beneficial and adverse effects from AREDS2 and other studies suggests that lutein/zeaxanthin could be more appropriate than β-carotene in AREDS-type supplements. Questions remain regarding the AREDS2 study results such as: whether the findings are generalizable to the population as a whole, what is the long-term safety profile of lutein/zeaxanthin supplementation, should other carotenoids be included in AREDS-type supplements, and at what optimal doses?
PURPOSE OF REVIEW: This review provides a perspective on the Age-related Eye Disease Study 2 (AREDS2) including a summary of the goals and rationale of the study, major findings, subsequent management recommendations, and questions that remain to be answered. RECENT FINDINGS: The primary goal of the AREDS2 was to evaluate the efficacy and safety of lutein plus zeaxanthin and/or omega-3 long-chain polyunsaturated acid supplementation in reducing the risk of developing advanced age-related macular degeneration (AMD). AREDS2 also investigated the effects of omitting β-carotene and reducing the concentration of zinc from the original AREDS formulation. Although primary analysis from the AREDS2 did not reveal a benefit of daily supplementation with lutein/zeaxanthin on AMD progression, secondary exploratory analyses suggested that lutein/zeaxanthin were helpful in reducing this risk. Comparison of low-dose to higher-dose zinc showed no significant benefit. SUMMARY: The overall evidence on the beneficial and adverse effects from AREDS2 and other studies suggests that lutein/zeaxanthin could be more appropriate than β-carotene in AREDS-type supplements. Questions remain regarding the AREDS2 study results such as: whether the findings are generalizable to the population as a whole, what is the long-term safety profile of lutein/zeaxanthin supplementation, should other carotenoids be included in AREDS-type supplements, and at what optimal doses?
Authors: G S Omenn; G E Goodman; M D Thornquist; J Balmes; M R Cullen; A Glass; J P Keogh; F L Meyskens; B Valanis; J H Williams; S Barnhart; M G Cherniack; C A Brodkin; S Hammar Journal: J Natl Cancer Inst Date: 1996-11-06 Impact factor: 13.506
Authors: Emily Y Chew; Traci E Clemons; John Paul Sangiovanni; Ronald P Danis; Frederick L Ferris; Michael J Elman; Andrew N Antoszyk; Alan J Ruby; David Orth; Susan B Bressler; Gary E Fish; George Baker Hubbard; Michael L Klein; Suresh R Chandra; Barbara A Blodi; Amitha Domalpally; Thomas Friberg; Wai T Wong; Philip J Rosenfeld; Elvira Agrón; Cynthia A Toth; Paul S Bernstein; Robert D Sperduto Journal: JAMA Ophthalmol Date: 2014-02 Impact factor: 7.389
Authors: Nathan Congdon; Benita O'Colmain; Caroline C W Klaver; Ronald Klein; Beatriz Muñoz; David S Friedman; John Kempen; Hugh R Taylor; Paul Mitchell Journal: Arch Ophthalmol Date: 2004-04
Authors: D Albanes; O P Heinonen; J K Huttunen; P R Taylor; J Virtamo; B K Edwards; J Haapakoski; M Rautalahti; A M Hartman; J Palmgren Journal: Am J Clin Nutr Date: 1995-12 Impact factor: 7.045